IAMA Therapeutics

Our purpose is to provide a therapeutic solution to children suffering from neurological conditions and provide their families with the support they need.

[IAMA Therapeutics @IAMABiotech]

Exciting News! We've initiated our First-in-Human Clinical Trial for the treatment of neurodevelopmental disorders with IAMA-6. We’ve successfully dosed the first two cohorts, and we’re moving forward to the third.

#IAMAtherapeutics #Neurodevelopment #ClinicalTrial #Biotech

[IAMA Therapeutics @IAMABiotech]

IAMA Therapeutics is excited to be onsite at the 42nd Annual @JPMorgan Healthcare Conference in San Francisco this week.

#JPM2024

#Biotech #Neuroscience #Epilepsy #Autism #Neurodevelopment #Investment #Partnering #Dealmaking

[IAMA Therapeutics @IAMABiotech]

IAMA Therapeutics announced that the Italian Medicines Agency (@Aifa_ufficiale) approved a Clinical Trial Application (CTA) to begin a Phase 1 Study of IAMA-6 for the treatment of #autism and #epilepsy. Read more: https://t.co/SChdxVvtqh

#Biotech #Neuroscience #Neurodevelopment

[IAMA Therapeutics @IAMABiotech]

IAMA Therapeutics is presenting new preclinical results supporting the potential for IAMA-6 as a disease-modifying therapy for drug-resistant epilepsies at the @AmEpilepsySoc #AES2023 Annual Meeting. Read more: https://t.co/f6Lt2Eobr2
#Biotech #LifeScience #Neuroscience #Epilepsy

[IAMA Therapeutics @IAMABiotech]

November is National Family Caregivers Month in the U.S., a time to honor the dedication of family members who provide essential care and support to their loved ones affected by pediatric central nervous system disorders and more. #Biotech #Neuroscience #Epilepsy #Autism

[IAMA Therapeutics @IAMABiotech]

This #NEAM2023, we honor the 3.4 million people living with epilepsy in the U.S. We are developing treatments to make a meaningful impact for children with CNS disorders like drug-resistant epilepsies. Learn more: https://t.co/PVfkkS0ghI #Epilepsy #Neuroscience #Neurodevelopment

[IAMA Therapeutics @IAMABiotech]

IAMA Therapeutics CEO @AndreaPMalizia will be attending the #JefferiesHealthcare Conference November 14-16 in London, UK.

#Biotech #LifeScience #Neuroscience #Neurodevelopment #Investment #Partnering #Dealmaking

[IAMA Therapeutics @IAMABiotech]

Today we honor #WorldMentalHealthDay. At IAMA, we are dedicated to unlocking major breakthroughs in neuroscience to develop personalized treatments for patients suffering from untreatable neurological conditions.

#Biotech #LifeScience #Neuroscience #Neurodevelopment

[IAMA Therapeutics @IAMABiotech]

IAMA Therapeutics announced it has signed a multi-phase agreement with Evotec for preclinical and clinical support in the anticipated Phase 1 study for IAMA-6. Read more: https://t.co/rxFXalOVRd

#Biotech #LifeScience #Neuroscience #Neurodevelopment #Epilepsy #Autism #RareDisease

[IAMA Therapeutics @IAMABiotech]

IAMA Therapeutics CEO @AndreaPMalizia will present at @SachsAssociates 23rd Annual Biotech in Europe Forum in Basel, Switzerland on September 20. Read more: https://t.co/OFDGvzfFir

#Sachs_BEF #Biotech #LifeScience #Neuroscience #Epilepsy #Neurodevelopment

[IAMA Therapeutics @IAMABiotech]

IAMA Therapeutics announced a sponsored research agreement with the Sapienza University of Rome, bringing us closer to our goal of making a meaningful impact on children affected by rare neurological disorders. Read more: https://t.co/sqOp5Z2PG6
#Biotech #Neurodevelopment

[IAMA Therapeutics @IAMABiotech]

#ICYMI IAMA Therapeutics announced the key additions of Paul Frohna M.D., Ph.D., PharmD, Pierandrea Muglia, M.D. and Elaine Wirrell, M.D., to its distinguished Scientific Advisory Board. Read more: https://t.co/mrhq8xzTwd

#Biotech #LifeScience #Neuroscience

[IAMA Therapeutics @IAMABiotech]

IAMA Therapeutics CEO @AndreaPMalizia will present at the #BIO2023 International Convention in Boston on June 7 at 10:45 AM ET. Read more: https://t.co/Gnj7NdP2vJ
#StandUpForScience #Biotech #Neuroscience #Epilepsy #Neurodevelopment #Investment #Partnering #Dealmaking

[IAMA Therapeutics @IAMABiotech]

IAMA Therapeutics CEO @AndreaPMalizia will be presenting at @BioCentury's #BioEquity Europe 2023 in Dublin during the Neurology, Neurodegeneration and Autoimmunity Sessions today, Monday 15th May. Learn more: https://t.co/FfN9tzyO52 #biotech #lifescience #neuroscience

[Zoe Cournia @zoecournia]

Marco Borgogno of @IAMABiotech presents the Iama SBDD neuroscience drug discovery pipeline #SBDD23

[IAMA Therapeutics @IAMABiotech]

@AndreaPMalizia will be presenting the advancement of @IAMABiotech R&D pipeline and investment opportunities at the next @LSXLeaders on Wednesday, 3rd May, in #london
#partnership #biotech #neuroscience #cognitive #seizures #epilepsy #autism #lifescience https://t.co/OoUvQXRjjC

[Spectrum (Autism Research News) @Spectrum]

“Our compound so far is much more selective against NKCC1 in the central nervous system,” says Andrea Malizia, Iama’s chief executive officer.

By @lalakat.
@devivo_marco @AndreaPMalizia @ProfMazzone
#autismresearch
https://t.co/i9scNLsT7o

[Marco De Vivo @devivo_marco]

If you are interested in, or somehow touched by, autism in the family… or other neuro-developmental disorders in kids … please read this.

A critical assessment of what’s going on regarding future medicines.

@IAMABiotech @IITalk #autism #epilepsy #drug #Discovery

[Spectrum (Autism Research News) @Spectrum]

.@IAMABiotech is hoping a new class of molecule will prove successful against an old target in autism.

By @lalakat.
@devivo_marco @AndreaPMalizia @ProfMazzone
#neurotwitter #autismresearch
https://t.co/YHoxL7lJ4y

[IAMA Therapeutics @IAMABiotech]

Building a better drug https://t.co/i0bZWSc6kC via @Spectrum